Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care
Objective: To report the use of risperidone long‐acting injection (RLAI) in a UK psychiatric service. Method: Retrospective case note review of all patients prescribed RLAI over a 35‐month period. In the mirror‐image analysis patients initiated on RLAI as in‐patients had the index admission attrib...
Gespeichert in:
| Veröffentlicht in: | Acta Psychiatrica Scandinavica 2007-07, Vol.116 (1), p.36-46 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 46 |
|---|---|
| container_issue | 1 |
| container_start_page | 36 |
| container_title | Acta Psychiatrica Scandinavica |
| container_volume | 116 |
| creator | Niaz, O. S. Haddad, P. M. |
| description | Objective: To report the use of risperidone long‐acting injection (RLAI) in a UK psychiatric service.
Method: Retrospective case note review of all patients prescribed RLAI over a 35‐month period. In the mirror‐image analysis patients initiated on RLAI as in‐patients had the index admission attributed to previous treatment.
Results: Patients prescribed RLAI had significantly higher baseline rates of drug misuse, alcohol misuse, unemployment and forensic markers than control patients prescribed oral antipsychotics. Most patients started RLAI because of poor compliance with oral antipsychotics. Inefficacy accounted for more discontinuations than intolerability. Fifty‐eight percent (39/67) of patients were continuing RLAI 12 months after initiation. Mirror‐image analysis (n = 74) showed that RLAI was associated with a reduction in the number of admissions (65 vs. 33, P |
| doi_str_mv | 10.1111/j.1600-0447.2006.00980.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70603885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19742429</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4230-da50bcb03e080a29bbea171d9b22a36b27010e79386321dc7bc6b18344328aca3</originalsourceid><addsrcrecordid>eNqNkU1vEzEQhlcIREvhLyALCW4bxvau13vgUEXQIio-RCq4WbPeSeKw8ab2piS_gz-Ml0StxAV88Yz8vPPhN8sYhwlP5_VqwhVADkVRTQSAmgDUGia7B9np3cPD7BQAeK5q-H6SPYlxldKSg36cnfCqLOuyrk-zX7OlC8M-n7tbYuveD8vIaLeh4MhbYv2cBRfHtO09sa73ixzt4PyCOb-iFPU-RQzZ9Qe2iXu7dDgEZ1mkcOtSAedtt21HHtnahdCH3K1xQQw9dvvo4tjC-XyDQ-o4MIuBnmaP5thFena8z7Lrd29n08v86tPF--n5VW4LISFvsYTGNiAJNKCom4aQV7ytGyFQqkZUwIGqWmolBW9t1VjVcC2LQgqNFuVZ9upQdxP6my3FwaxdtNR16KnfRlOBAql1-U-Q11UhClEn8MVf4KrfhrTpyJRaKa2KBOkDZEMfY6C52YT0J2FvOJjRXrMyo4tmdNGM9po_9ppdkj4_1t82a2rvhUc_E_DyCGC02M0DeuviPae1EJKPG705cD9dR_v_HsCcTz9_TVHS5we9iwPt7vQYfhhVyao03z5emGLKv8wup8pI-RsU79D4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195866864</pqid></control><display><type>article</type><title>Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Niaz, O. S. ; Haddad, P. M.</creator><creatorcontrib>Niaz, O. S. ; Haddad, P. M.</creatorcontrib><description>Objective: To report the use of risperidone long‐acting injection (RLAI) in a UK psychiatric service.
Method: Retrospective case note review of all patients prescribed RLAI over a 35‐month period. In the mirror‐image analysis patients initiated on RLAI as in‐patients had the index admission attributed to previous treatment.
Results: Patients prescribed RLAI had significantly higher baseline rates of drug misuse, alcohol misuse, unemployment and forensic markers than control patients prescribed oral antipsychotics. Most patients started RLAI because of poor compliance with oral antipsychotics. Inefficacy accounted for more discontinuations than intolerability. Fifty‐eight percent (39/67) of patients were continuing RLAI 12 months after initiation. Mirror‐image analysis (n = 74) showed that RLAI was associated with a reduction in the number of admissions (65 vs. 33, P < 0.005) and in total in‐patient days (4550 vs. 2188 days, P < 0.005). The mean reduction in in‐patient care was 29 days per patient‐year of treatment, equivalent to a net financial saving over the acquisition and administration costs of RLAI of £1172.
Conclusion: Risperidone long‐acting injection was associated with reduced in‐patient care and was cost‐effective.</description><identifier>ISSN: 0001-690X</identifier><identifier>EISSN: 1600-0447</identifier><identifier>EISSN: 0065-1591</identifier><identifier>DOI: 10.1111/j.1600-0447.2006.00980.x</identifier><identifier>PMID: 17559599</identifier><identifier>CODEN: APYSA9</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Aged ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - economics ; Antipsychotic Agents - therapeutic use ; Biological and medical sciences ; Clinical outcomes ; Cost-Benefit Analysis ; Delayed-Action Preparations - administration & dosage ; Delayed-Action Preparations - economics ; Delayed-Action Preparations - therapeutic use ; depot formulation ; Drug therapy ; Female ; Health Care Costs ; Hospitalization ; Humans ; Injections, Intravenous ; Inpatient care ; long-acting risperidone injection ; Male ; Medical sciences ; Mental disorders ; Mental Health Services - economics ; Middle Aged ; Neuropharmacology ; outcome assessment (health care) ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; re-hospitalisation ; Recurrence ; relapse ; Risperidone - administration & dosage ; Risperidone - economics ; Risperidone - therapeutic use ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenia - economics ; Schizophrenia - rehabilitation ; Time Factors ; tolerability ; United Kingdom</subject><ispartof>Acta Psychiatrica Scandinavica, 2007-07, Vol.116 (1), p.36-46</ispartof><rights>2007 INIST-CNRS</rights><rights>2007 The Authors Journal Compilation 2007 Blackwell Munksgaard</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4230-da50bcb03e080a29bbea171d9b22a36b27010e79386321dc7bc6b18344328aca3</citedby><cites>FETCH-LOGICAL-c4230-da50bcb03e080a29bbea171d9b22a36b27010e79386321dc7bc6b18344328aca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-0447.2006.00980.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-0447.2006.00980.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18822315$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17559599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niaz, O. S.</creatorcontrib><creatorcontrib>Haddad, P. M.</creatorcontrib><title>Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care</title><title>Acta Psychiatrica Scandinavica</title><addtitle>Acta Psychiatr Scand</addtitle><description>Objective: To report the use of risperidone long‐acting injection (RLAI) in a UK psychiatric service.
Method: Retrospective case note review of all patients prescribed RLAI over a 35‐month period. In the mirror‐image analysis patients initiated on RLAI as in‐patients had the index admission attributed to previous treatment.
Results: Patients prescribed RLAI had significantly higher baseline rates of drug misuse, alcohol misuse, unemployment and forensic markers than control patients prescribed oral antipsychotics. Most patients started RLAI because of poor compliance with oral antipsychotics. Inefficacy accounted for more discontinuations than intolerability. Fifty‐eight percent (39/67) of patients were continuing RLAI 12 months after initiation. Mirror‐image analysis (n = 74) showed that RLAI was associated with a reduction in the number of admissions (65 vs. 33, P < 0.005) and in total in‐patient days (4550 vs. 2188 days, P < 0.005). The mean reduction in in‐patient care was 29 days per patient‐year of treatment, equivalent to a net financial saving over the acquisition and administration costs of RLAI of £1172.
Conclusion: Risperidone long‐acting injection was associated with reduced in‐patient care and was cost‐effective.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - economics</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical outcomes</subject><subject>Cost-Benefit Analysis</subject><subject>Delayed-Action Preparations - administration & dosage</subject><subject>Delayed-Action Preparations - economics</subject><subject>Delayed-Action Preparations - therapeutic use</subject><subject>depot formulation</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health Care Costs</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Inpatient care</subject><subject>long-acting risperidone injection</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental disorders</subject><subject>Mental Health Services - economics</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>outcome assessment (health care)</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>re-hospitalisation</subject><subject>Recurrence</subject><subject>relapse</subject><subject>Risperidone - administration & dosage</subject><subject>Risperidone - economics</subject><subject>Risperidone - therapeutic use</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - economics</subject><subject>Schizophrenia - rehabilitation</subject><subject>Time Factors</subject><subject>tolerability</subject><subject>United Kingdom</subject><issn>0001-690X</issn><issn>1600-0447</issn><issn>0065-1591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1vEzEQhlcIREvhLyALCW4bxvau13vgUEXQIio-RCq4WbPeSeKw8ab2piS_gz-Ml0StxAV88Yz8vPPhN8sYhwlP5_VqwhVADkVRTQSAmgDUGia7B9np3cPD7BQAeK5q-H6SPYlxldKSg36cnfCqLOuyrk-zX7OlC8M-n7tbYuveD8vIaLeh4MhbYv2cBRfHtO09sa73ixzt4PyCOb-iFPU-RQzZ9Qe2iXu7dDgEZ1mkcOtSAedtt21HHtnahdCH3K1xQQw9dvvo4tjC-XyDQ-o4MIuBnmaP5thFena8z7Lrd29n08v86tPF--n5VW4LISFvsYTGNiAJNKCom4aQV7ytGyFQqkZUwIGqWmolBW9t1VjVcC2LQgqNFuVZ9upQdxP6my3FwaxdtNR16KnfRlOBAql1-U-Q11UhClEn8MVf4KrfhrTpyJRaKa2KBOkDZEMfY6C52YT0J2FvOJjRXrMyo4tmdNGM9po_9ppdkj4_1t82a2rvhUc_E_DyCGC02M0DeuviPae1EJKPG705cD9dR_v_HsCcTz9_TVHS5we9iwPt7vQYfhhVyao03z5emGLKv8wup8pI-RsU79D4</recordid><startdate>200707</startdate><enddate>200707</enddate><creator>Niaz, O. S.</creator><creator>Haddad, P. M.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>200707</creationdate><title>Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care</title><author>Niaz, O. S. ; Haddad, P. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4230-da50bcb03e080a29bbea171d9b22a36b27010e79386321dc7bc6b18344328aca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - economics</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical outcomes</topic><topic>Cost-Benefit Analysis</topic><topic>Delayed-Action Preparations - administration & dosage</topic><topic>Delayed-Action Preparations - economics</topic><topic>Delayed-Action Preparations - therapeutic use</topic><topic>depot formulation</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health Care Costs</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Inpatient care</topic><topic>long-acting risperidone injection</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental disorders</topic><topic>Mental Health Services - economics</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>outcome assessment (health care)</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>re-hospitalisation</topic><topic>Recurrence</topic><topic>relapse</topic><topic>Risperidone - administration & dosage</topic><topic>Risperidone - economics</topic><topic>Risperidone - therapeutic use</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - economics</topic><topic>Schizophrenia - rehabilitation</topic><topic>Time Factors</topic><topic>tolerability</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niaz, O. S.</creatorcontrib><creatorcontrib>Haddad, P. M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Acta Psychiatrica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niaz, O. S.</au><au>Haddad, P. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care</atitle><jtitle>Acta Psychiatrica Scandinavica</jtitle><addtitle>Acta Psychiatr Scand</addtitle><date>2007-07</date><risdate>2007</risdate><volume>116</volume><issue>1</issue><spage>36</spage><epage>46</epage><pages>36-46</pages><issn>0001-690X</issn><eissn>1600-0447</eissn><eissn>0065-1591</eissn><coden>APYSA9</coden><abstract>Objective: To report the use of risperidone long‐acting injection (RLAI) in a UK psychiatric service.
Method: Retrospective case note review of all patients prescribed RLAI over a 35‐month period. In the mirror‐image analysis patients initiated on RLAI as in‐patients had the index admission attributed to previous treatment.
Results: Patients prescribed RLAI had significantly higher baseline rates of drug misuse, alcohol misuse, unemployment and forensic markers than control patients prescribed oral antipsychotics. Most patients started RLAI because of poor compliance with oral antipsychotics. Inefficacy accounted for more discontinuations than intolerability. Fifty‐eight percent (39/67) of patients were continuing RLAI 12 months after initiation. Mirror‐image analysis (n = 74) showed that RLAI was associated with a reduction in the number of admissions (65 vs. 33, P < 0.005) and in total in‐patient days (4550 vs. 2188 days, P < 0.005). The mean reduction in in‐patient care was 29 days per patient‐year of treatment, equivalent to a net financial saving over the acquisition and administration costs of RLAI of £1172.
Conclusion: Risperidone long‐acting injection was associated with reduced in‐patient care and was cost‐effective.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17559599</pmid><doi>10.1111/j.1600-0447.2006.00980.x</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-690X |
| ispartof | Acta Psychiatrica Scandinavica, 2007-07, Vol.116 (1), p.36-46 |
| issn | 0001-690X 1600-0447 0065-1591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70603885 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Adult and adolescent clinical studies Aged Antipsychotic Agents - administration & dosage Antipsychotic Agents - economics Antipsychotic Agents - therapeutic use Biological and medical sciences Clinical outcomes Cost-Benefit Analysis Delayed-Action Preparations - administration & dosage Delayed-Action Preparations - economics Delayed-Action Preparations - therapeutic use depot formulation Drug therapy Female Health Care Costs Hospitalization Humans Injections, Intravenous Inpatient care long-acting risperidone injection Male Medical sciences Mental disorders Mental Health Services - economics Middle Aged Neuropharmacology outcome assessment (health care) Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses re-hospitalisation Recurrence relapse Risperidone - administration & dosage Risperidone - economics Risperidone - therapeutic use Schizophrenia Schizophrenia - drug therapy Schizophrenia - economics Schizophrenia - rehabilitation Time Factors tolerability United Kingdom |
| title | Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T00%3A04%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thirty-five%20months%20experience%20of%20risperidone%20long-acting%20injection%20in%20a%20UK%20psychiatric%20service%20including%20a%20mirror-image%20analysis%20of%20in-patient%20care&rft.jtitle=Acta%20Psychiatrica%20Scandinavica&rft.au=Niaz,%20O.%20S.&rft.date=2007-07&rft.volume=116&rft.issue=1&rft.spage=36&rft.epage=46&rft.pages=36-46&rft.issn=0001-690X&rft.eissn=1600-0447&rft.coden=APYSA9&rft_id=info:doi/10.1111/j.1600-0447.2006.00980.x&rft_dat=%3Cproquest_cross%3E19742429%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195866864&rft_id=info:pmid/17559599&rfr_iscdi=true |